Tumor Microenvironment As a Therapeutic Target in Melanoma Treatment
Overview
Authors
Affiliations
The role of the tumor microenvironment in tumor growth and therapy has recently attracted more attention in research and drug development. The ability of the microenvironment to trigger tumor maintenance, progression, and resistance is the main cause for treatment failure and tumor relapse. Accumulated evidence indicates that the maintenance and progression of tumor cells is determined by components of the microenvironment, which include stromal cells (endothelial cells, fibroblasts, mesenchymal stem cells, and immune cells), extracellular matrix (ECM), and soluble molecules (chemokines, cytokines, growth factors, and extracellular vesicles). As a solid tumor, melanoma is not only a tumor mass of monolithic tumor cells, but it also contains supporting stroma, ECM, and soluble molecules. Melanoma cells are continuously in interaction with the components of the microenvironment. In the present review, we focus on the role of the tumor microenvironment components in the modulation of tumor progression and treatment resistance as well as the impact of the tumor microenvironment as a therapeutic target in melanoma.
Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials.
Mayasin Y, Osinnikova M, Kharisova C, Kitaeva K, Filin I, Gorodilova A Cells. 2024; 13(22).
PMID: 39594665 PMC: 11592585. DOI: 10.3390/cells13221917.
Shan Z, Liu F Front Immunol. 2024; 15:1441410.
PMID: 39234260 PMC: 11373357. DOI: 10.3389/fimmu.2024.1441410.
Trandafir C, Closca R, Poenaru M, Sarau O, Sarau C, Rakitovan M Cancers (Basel). 2024; 16(16).
PMID: 39199634 PMC: 11352549. DOI: 10.3390/cancers16162863.
Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini G J Exp Clin Cancer Res. 2024; 43(1):226.
PMID: 39143551 PMC: 11325673. DOI: 10.1186/s13046-024-03151-3.
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling.
Slominski R, Kim T, Janjetovic Z, Brozyna A, Podgorska E, Dixon K Cancers (Basel). 2024; 16(12).
PMID: 38927967 PMC: 11201527. DOI: 10.3390/cancers16122262.